| ISIN | CH0113817065 |
|---|---|
| Valor Number | 11381706 |
| Bloomberg Global ID | BBG0017T9CP3 |
| Fund Name | Bellevue Biotech AA CHF |
| Fund Provider |
Bellevue Asset Management AG
Zürich, Switzerland Phone: +41 44 267 67 00 E-Mail: info@bellevue.ch Web: www.bellevue.ch |
| Fund Provider | Bellevue Asset Management AG |
| Representative in Switzerland | |
| Distributor(s) |
Zürcher Kantonalbank Zürich Phone: +41 44 293 93 93 |
| Asset Class | Equities |
| EFC Category | |
| Distribution Policy | Distribution |
| Home Country | Switzerland |
| Issuing Condition | Special conditions apply to the issue of units |
| Redemption Condition | Special conditions apply to the redemption of units |
| Investment Strategy *** | N/A |
| Peculiarities |
| Current Price * | 3,789.17 CHF | 18.12.2025 |
|---|---|---|
| Previous Price * | 3,825.49 CHF | 17.12.2025 |
| 52 Week High * | 4,026.13 CHF | 26.11.2025 |
| 52 Week Low * | 2,772.30 CHF | 10.04.2025 |
| NAV * | 3,789.17 CHF | 18.12.2025 |
| Issue Price * | ||
| Redemption Price * | ||
| Closing Price * | ||
| Indicative Minimum Price | ||
| Fund Assets *** | 24,007,570 | |
| Unit/Share Assets *** | 12,609,249 | |
| Trading Information SIX | ||
| YTD Performance | +14.69% |
31.12.2024 - 18.12.2025
31.12.2024 18.12.2025 |
|---|---|---|
| 1 month | -1.87% |
18.11.2025 - 18.12.2025
18.11.2025 18.12.2025 |
| 3 months | +14.05% |
18.09.2025 - 18.12.2025
18.09.2025 18.12.2025 |
| 6 months | +25.20% |
18.06.2025 - 18.12.2025
18.06.2025 18.12.2025 |
| 1 year | +16.24% |
18.12.2024 - 18.12.2025
18.12.2024 18.12.2025 |
| 2 years | +26.23% |
18.12.2023 - 18.12.2025
18.12.2023 18.12.2025 |
| 3 years | +9.88% |
19.12.2022 - 18.12.2025
19.12.2022 18.12.2025 |
| 5 years | +1.20% |
18.12.2020 - 18.12.2025
18.12.2020 18.12.2025 |
| Equity Participation Rate in % | 85.90 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Real Estate Rate in % | 0.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI | 11.6387 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI Date | 18.12.2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc | 7.72% | |
|---|---|---|
| Gilead Sciences Inc | 7.52% | |
| Amgen Inc | 7.35% | |
| Regeneron Pharmaceuticals Inc | 5.59% | |
| Alnylam Pharmaceuticals Inc | 5.08% | |
| AstraZeneca PLC ADR | 4.27% | |
| Insmed Inc | 4.23% | |
| argenx SE ADR | 2.72% | |
| Biogen Inc | 2.12% | |
| BridgeBio Pharma Inc | 2.03% | |
| Last data update | 31.10.2025 | |
| TER | 1.82% |
|---|---|
| TER date | 30.09.2024 |
| Performance Fee *** | 10.00% |
| PTR | |
| Max. Management Fee *** | 2.00% |
| Ongoing Charges *** | |
|
SRRI ***
|
|
| SRRI date *** | 30.11.2025 |